Braj News Magazine

Cystinosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Cystinosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 17
17:50 2023
Cystinosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Cystinosis Pipeline Insights
DelveInsight’s ‘Cystinosis Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain.

DelveInsight’s Cystinosis Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain.

Key Takeaways from the Cystinosis Pipeline Report

  • Over 5+ Cystinosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Cystinosis market would significantly increase market revenue. 
  • Leading Cystinosis companies developing novel drug candidates to improve the Cystinosis treatment landscape include AVROBIO, Nacuity Pharmaceuticals, and others.
  • Promising Cystinosis pipeline therapies in various stages of development include AVR RD 04, NP-3,and others.

Cystinosis Overview

Cystinosis is characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells. Excess cystine damages cells and often forms crystals that can build up and cause problems in many organs and tissues.

Cystinosis Pipeline Analysis: Drug Profile

AVR RD 04: AVROBIO

AVROBIO’s investigational gene therapy for cystinosis is being studied in a Phase 1/2 investigational trial sponsored by the University of California, San Diego. The first patient was dosed in October 2019. The single-arm trial is expected to enroll four adults and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine, the standard of care for cystinosis.

Discover more about the emerging Cystinosis drugs @ Cystinosis Treatment Drugs

Cystinosis Key Companies

  • AVROBIO
  • Nacuity Pharmaceuticals

Cystinosis Pipeline Therapies

  • AVR RD 04
  • NP-3

Cystinosis Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Cystinosis Pipeline Report 

  • Coverage: Global 
  • Key Cystinosis Companies: AVROBIO, Nacuity Pharmaceuticals, and others
  • Key Cystinosis Pipeline Therapies: AVR RD 04, NP-3, and others

Find out more about the Cystinosis treatment options in development @ Cystinosis Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Cystinosis pipeline segment 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/